Skip to main content

Table 3 Group division and results of antibodies, clinical signs and lung lesions in efficacy test

From: Safety and immunogenicity of an attenuated Chinese pseudorabies variant by dual deletion of TK&gE genes

Groups    A B C D E F
Virus tested    PRVΔTK&gE-AH02 Bartha K61 / /
Dosage (TCID50)    103 104 105 105 / /
Inoculation route    Intramuscularly
ELISA antibodies against PRV gB or gE B.V. gB+ 0a/4b 0/4 0/4 0/4 0/4 0/4
gE+ 0/4 0/4 0/4 0/4 0/4 0/4
7d P.V. gB+ 4/4 4/4 4/4 4/4 0/4 0/4
gE+ 0/4 0/4 0/4 0/4 0/4 0/4
14 d P.C. gB+ 4/4 4/4 4/4 4/4 0/4 0/4
gE+ 4/4 4/4 4/4 4/4 1/1 0/4
Clinical signs P.V.   0/4 0/4 0/4 0/4 0/4 0/4
Fever frequency (≥40.5 °C) P.V.   0/4 0/4 0/4 0/4 0/4 0/4
Virus shedding P.V.   0/4 0/4 0/4 0/4 / /
Fever frequency (≥40.5 °C) P.C.   0/4 0/4 0/4 4/4 4/4 0/4
Clinical signs P.C. Morbidity 0/4 0/4 0/4 0/4 4/4 0/4
Duration (days) / / / / 4~ 9 /
Mortality 0/4 0/4 0/4 0/4 3/4 0/4
Virus shedding P.C. Frequency 0/4 0/4 0/4 4/4 4/4 0/4
Duration (days) / / / 3~ 5 2~ 9 /
Lung lesions   0/4 0/4 0/4 2/4 4/4 0/4
  1. B.V. means before vaccination, P.V. means post vaccination, P.C. means post challenge, gB+ means antibodies against PRV gB positive, gE+ means antibodies against PRV gE positive, “a” indicates the number of piglets positive; “b” indicates the number of piglets in the group